More on RVMD
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $149.23 |
|
|||
| Open | $150.40 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $154.74 | ||||
| Day Low | $149.67 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 1,581,059 | ||||
- Form 144 Revolution Medicines, Filed by: Horn Margaret A
- UBS Reiterates Buy Rating on Revolution (RVMD) Following Trial Data Release
- Revolution (RVMD) trading up 1%, RBC says that's about what they expected it to trade
- Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
- Revolution (RVMD) PT Raised to $182 at RBC Capital
- Revolution Medicines (RVMD) call put ratio 3.3 calls to 1 put after presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO
- Revolution (RVMD) PT Raised to $195 at H.C. Wainwright
- TD Cowen Reiterates Buy Rating and Top Pick on Revolution (RVMD)
- Revolution (RVMD) Reiterated at Buy by Stifel
- Revolution (RVMD) PT Raised to $195 at Oppenheimer
Entities mentioned with RVMD
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Cowen & Co | View Related Stories »
- JPMorgan | View Related Stories »
- Guggenheim | View Related Stories »
- 13G | View Related Stories »
- Show More...
